Neuroprogression in schizophrenia: Pathways underpinning clinical staging and therapeutic corollaries
- 6 May 2014
- journal article
- review article
- Published by SAGE Publications in Australian & New Zealand Journal of Psychiatry
- Vol. 48 (6) , 512-529
Abstract
Whilst dopaminergic dysfunction remains a necessary component involved in the pathogenesis of schizophrenia, our current pharmacological armoury of dopamine antagonists does little to control the negative symptoms of schizophrenia. This suggests other pathological processes must be implicated. This paper aims to elaborate on such theories. Data for this review were sourced from the electronic database PUBMED, and was not limited by language or date of publication. It has been suggested that multiple ‘hits’ may be required to unveil the clinical syndrome in susceptible individuals. Such hits potentially first occur in utero, leading to neuronal disruption, epigenetic changes and the establishment of an abnormal inflammatory response. The development of schizophrenia may therefore potentially be viewed as a neuroprogressive response to these early stressors, driven on by changes in tryptophan catabolite (TRYCAT) metabolism, reactive oxygen species handling and N-methyl d-aspartate (NMDA) circuitry. Given the potential for such progression over time, it is prudent to explore the new treatment strategies which may be implemented before such changes become established. Outside of the dopaminergic model, the potential pathogenesis of schizophrenia has yet to be fully elucidated, but common themes include neuropil shrinkage, the development of abnormal neuronal circuitry, and a chronic inflammatory state which further disrupts neuronal function. Whilst some early non-dopaminergic treatments show promise, none have yet to be fully studied in appropriately structured randomized controlled trials and they remain little more than potential attractive targets.Keywords
This publication has 217 references indexed in Scilit:
- Future perspectives on the treatment of cognitive deficits and negative symptoms in schizophreniaWorld Psychiatry, 2013
- Behavioral and neurochemical consequences of cortical oxidative stress on parvalbumin-interneuron maturation in rodent models of schizophreniaNeuropharmacology, 2012
- Perisomatic inhibition and cortical circuit dysfunction in schizophreniaCurrent Opinion in Neurobiology, 2011
- Progressive Brain Change in Schizophrenia: A Prospective Longitudinal Study of First-Episode SchizophreniaBiological Psychiatry, 2011
- Clozapine Protects Dopaminergic Neurons from Inflammation-Induced Damage by Inhibiting Microglial OveractivationJournal of Neuroimmune Pharmacology, 2011
- Oxidative stress in schizophrenia: An integrated approachNeuroscience & Biobehavioral Reviews, 2011
- Mitochondrial dysfunction and pathology in bipolar disorder and schizophreniaInternational Journal of Developmental Neuroscience, 2010
- GABAA receptors and their associated proteins: Implications in the etiology and treatment of schizophrenia and related disordersNeuropharmacology, 2009
- Dopamine and serotonin levels following prenatal viral infection in mouse—Implications for psychiatric disorders such as schizophrenia and autismEuropean Neuropsychopharmacology, 2008
- Disease-specific alterations in glutamatergic neurotransmission on inhibitory interneurons in the prefrontal cortex in schizophreniaBrain Research, 2008